Search

Displaying results 191 - 200 of 332 in total
  1. Drug

    Povetacicept

    go.drugbank.com/drugs/DB18996
    Investigational

    Povetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).

  2. Drug

    Bifenthrin

    go.drugbank.com/drugs/DB15056
    Experimental

    Bifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).

  3. Drug

    Etozoline

    go.drugbank.com/drugs/DB08982
    Experimental

    Etozoline is marketed in Europe under the names Diulozin, Elkapin, and Etopinil. Etozoline is a loop diuretic.

  4. Drug

    Diethylamino hydroxybenzoyl hexyl benzoate

    go.drugbank.com/drugs/DB11269
    Approved

    Diethylamino hydroxybenzoyl hexyl benzoate was approved in Europe in 2005, and is also marketed in the U.S., South America, Mexico, Japan and Taiwan.

  5. Drug

    Estriol

    go.drugbank.com/drugs/DB04573
    ApprovedInvestigationalVet approved

    It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.

  6. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    [A251805] Metamizole is still used in certain countries in Europe, Asia and South America.[A251805]

  7. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan.

  8. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  9. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    [L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411]

  10. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and